Parinaz Aliahmad
About Parinaz Aliahmad
Parinaz Aliahmad, PhD, is the Head of Research & Development and presented on the potential of self-replicating RNA at the 2024 ASGCT Annual Meeting.
Parinaz Aliahmad: Head of Research & Development
Parinaz Aliahmad currently holds the position of Head of Research & Development. With a significant academic background and extensive expertise in the field, she oversees the strategic direction and innovation of the company's research efforts. Her leadership role involves guiding teams, managing projects, and ensuring the alignment of research initiatives with organizational goals.
Parinaz Aliahmad's PhD and Expertise
Parinaz Aliahmad holds a PhD, underscoring her advanced knowledge and specialization in her field. This level of education equips her with a strong foundation in research methodologies, analytical skills, and a deep understanding of complex scientific concepts. Her academic background supports her role in driving forward-looking research and development projects.
2024 ASGCT Annual Meeting Presentation by Parinaz Aliahmad
At the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, Parinaz Aliahmad delivered an oral presentation. She discussed the broad potential of self-replicating RNA (srRNA) as a new treatment modality, highlighting its applicability across a wide range of disease areas. This presentation showcased her knowledge and the innovative research her team is conducting.
Innovative Use of srRNA Vectors by Parinaz Aliahmad
In her presentation at the ASGCT Annual Meeting, Parinaz Aliahmad highlighted the development and use of novel self-replicating RNA (srRNA) vectors. These vectors are designed to achieve protective immunity at ultra-low doses with minimal reactogenicity, demonstrating a significant advancement in RNA technology. This work represents a promising step forward in therapeutic applications.
Increased Protein Expression with Novel srRNA Vectors
Parinaz Aliahmad provided insights into the increased expression and improved durability of encoded proteins using novel self-replicating RNA (srRNA) vectors. Compared to other RNA technologies, these novel vectors offer enhanced performance, which could lead to more effective and long-lasting treatments. This aspect of her research underscores the potential for significant advancements in the field of gene and cell therapy.